The fast pace of innovation in IT offers compelling investment opportunities
Truffle Capital is a pioneer investor in the exciting field of Energy
Biotechnology has radically transformed medicine over the past 25 years
Immune Targeting Systems (ITS) Ltd is developing synthetic vaccines for mutating viruses. The company’s enabling T-cell vaccine platform enables it to target highly conserved parts of the virus (“antigens”) and direct a T-cell immune response to those cells in the body infected with one of these difficult viruses. The fluoropeptide vaccine technology then delivers these antigens into the body and promotes robust T-cell immunity without requiring potentially toxic adjuvants which are normally used with vaccines to boost the responses achieved.
The first patient has been treated in sept 2010 in a Phase-I trial with its synthetic universal influenza vaccine (FP-01). Commencement of trials follows receipt of UK Regulatory Authority (MHRA) approval.
Over the same period the company received £500,000 in new investment from Esperante Ventures (UK). This brings total Series-A funding to £14.5 million from the syndicate of investors HealthCap (Sweden), London Technology Fund (UK), Novartis Venture Fund (US & Basel) and Truffle Capital.
Truffle Capital board member: Dr. Philippe Pouletty